All In Biotech

Drug Trial Radar · NCT04256174

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

A Phase 1, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AK120 in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Aug 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Jun 15, 2020

Primary completion

Oct 29, 2021

Study completion Oct 29, 2021

Sponsor

Lead sponsor
Akesobio Australia Pty LtdIndustry
Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A dose escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and subjects with moderate- to- severe atopic dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • AK120 or placebo- Part 1- Cohort 1Drug

    Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects

  • AK120 or placebo- Part 1- Cohort 2Drug

    Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects

  • AK120 or placebo- Part 1- Cohort 3Drug

    Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects

  • AK120 or placebo- Part 1- Cohort 4Drug

    Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects

  • AK120 or placebo- Part 1- Cohort 5Drug

    Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects

  • AK120 or placebo- Part 2- Cohort 1Drug

    Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis

  • AK120 or placebo- Part 2- Cohort 2Drug

    Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis

  • AK120 or placebo- Part 2- Cohort 3Drug

    Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis

  • AK120 or placebo- Part 2- Cohort 4Drug

    Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events(AEs)/serious adverse events(SAEs)Time frame: From signing of informed consent through through 12 weeks post-dose

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, Australia

  • Sinclair Dermatology

    East Melbourne, Australia

  • Peninsula Specialist Centre

    Kippa-Ring, Australia

  • Scientia Clinical Research Ltd

    Randwick, Australia

  • Emeritus Sydney

    Botany, New South Wales, Australia

  • Emeritus Melbourne

    Camberwell, Victoria, Australia

  • Optimal Clinical Trials

    Auckland, New Zealand

  • Christchurch Clinical Studies Trust

    Christchurch, New Zealand

  • Southern Clinical Trials - Christchurch

    Christchurch, New Zealand

  • P3 Research Hawkes Bay

    Havelock North, New Zealand

  • P3 Research Tauranga

    Tauranga, New Zealand

  • P3 Research Wellington

    Wellington, New Zealand

  • Southern Clinical Trials - Waitemata

    Birkenhead, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.